Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates
- PMID: 9825230
Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates
Abstract
A total of 1,116 clinically isolated strains belonging to Staphylococcus aureus (200), Staphylococcus epidermidis (200), Streptococcus pneumoniae (20), Escherchia coli (200), Klebsiella spp. (177), Serratia marcescens (22), Pseudomonas aeruginosa (224), Haemophilus influenzae (35) and Salmonella (38) from the Department of Infectious Diseases, La Sapienza University in Rome (Italy) were tested against three fluoroquinolones (ofloxacin, ciprofloxacin and levofloxacin) and 10 other antibiotics (augmentin, ampicillin, cefaclor, cefixime, cefotaxime, cotrimoxazole, gentamicin, minocycline, oxacillin and vancomycin). Fluoroquinolones inhibited essentially about 100% of H. influenzae, Salmonella and S. pneumoniae, more than 75% of Staphylococcus including methicillin-resistant strains, and about 90% of Enterobacteriaceae and 50% of P. aeruginosa. Minimal inhibitory concentration values ranged from < 0.015 to > 32 micrograms/ml for Klebsiella, S. aureus and epidermidis, E. coli and P. aeruginosa; from < 0.015 to 2 micrograms/ml for Salmonella; from 0.03 to 16 micrograms/ml for Serratia; from < 0.015 to 1 microgram/ml for Haemophilus; and from 0.5 to 2 micrograms/ml for S. pneumoniae. Levofloxacin and to a lesser extent ofloxacin and ciprofloxacin, generally exhibited a greater activity than the other agents against both Gram-positive and Gram-negative bacteria. Regarding the distribution of resistant strains in Italy, we found a peculiar pattern of resistance as far as E. coli and P. aeruginosa were concerned. Quality control parameters are also summarized. S. epidermidis resulted as a new emergent pathogen especially in immunocompromised patients and its level of sensitivity has been modified over the last few years. In fact, the percentage of resistant strains to antibiotics or the percentage of methicillin-resistant isolates (in our study 35%), has gradually increased. Levofloxacin and ofloxacin showed good activity against staphylococcal strains compared with the majority of other antibiotics. These results suggest that the newer quinolones are promising antimicrobial agents for various infections.
Similar articles
-
In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.J Microbiol Immunol Infect. 2001 Sep;34(3):178-84. J Microbiol Immunol Infect. 2001. PMID: 11605808
-
Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.Microbios. 1993;74(300):147-54. Microbios. 1993. PMID: 8396196
-
Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.Diagn Microbiol Infect Dis. 2005 Jul;52(3):187-93. doi: 10.1016/j.diagmicrobio.2005.05.004. Diagn Microbiol Infect Dis. 2005. PMID: 16105563
-
In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.Clin Infect Dis. 2000 Aug;31 Suppl 2:S16-23. doi: 10.1086/314054. Clin Infect Dis. 2000. PMID: 10984323 Review.
-
Overview of the fluoroquinolone antibiotics.Pharmacotherapy. 1993 Mar-Apr;13(2 Pt 2):4S-17S. Pharmacotherapy. 1993. PMID: 8386356 Review.
Cited by
-
Ciprofloxacin bioavailability is enhanced by oral co-administration with phenazopyridine: a pharmacokinetic study in a Mexican population.Clin Drug Investig. 2006;26(6):323-8. doi: 10.2165/00044011-200626060-00003. Clin Drug Investig. 2006. PMID: 17163266 Clinical Trial.
-
N-substituted piperazinyl sarafloxacin derivatives: synthesis and in vitro antibacterial evaluation.Daru. 2018 Dec;26(2):199-207. doi: 10.1007/s40199-018-0226-0. Epub 2018 Nov 3. Daru. 2018. PMID: 30392156 Free PMC article.
-
Methyl gallate from Galla rhois successfully controls clinical isolates of Salmonella infection in both in vitro and in vivo systems.PLoS One. 2014 Jul 21;9(7):e102697. doi: 10.1371/journal.pone.0102697. eCollection 2014. PLoS One. 2014. PMID: 25048362 Free PMC article.
-
Bioengineered Ciprofloxacin-Loaded Chitosan Nanoparticles for the Treatment of Bovine Mastitis.Biomedicines. 2022 Dec 19;10(12):3282. doi: 10.3390/biomedicines10123282. Biomedicines. 2022. PMID: 36552038 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous